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Background: Zenpep (APT-1008) is a pancreatic enzyme product for the treatment of exocrine pancreatic insufﬁciency (EPI) associated with cystic
ﬁbrosis (CF).
Methods: Zenpep and Kreon, both containing 25,000 lipase units, were compared in a randomised, double-blind, crossover, non-inferiority study
for CF-associated EPI in patients aged ≥12 years. Patients on a standardised diet and stabilised treatment were randomised to two treatment
sequences: Zenpep/Kreon or Kreon/Zenpep. The primary efﬁcacy endpoint was the coefﬁcient of fat absorption over 72 h (CFA-72 h).
Results: 96 patients (mean age 19.2 years, 60.4% males) were randomised with 83 completers of both sequences comprising the efﬁcacy
population. Zenpep demonstrated non-inferiority and equivalence to Kreon in fat absorption (LS mean CFA-72 h: Zenpep, 84.1% [SE 1.1] vs.
Kreon, 85.3% [SE 1.1]; p = 0.297). Safety and tolerability were similar.
Conclusions: Zenpep is comparable with Kreon in efﬁcacy and safety for the treatment of adolescents and adults with CF-associated EPI.
NCT01641393
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Cystic ﬁbrosis; Clinical trial; Pancreatic enzyme product (PEP); Exocrine pancreatic insufﬁciency (EPI); Zenpep; Enzepi1. Introduction
Approximately 85% of patients with cystic fibrosis (CF)
exhibit signs of exocrine pancreatic insufficiency (EPI) in addition,
,
t
,
t
,to respiratory signs and symptoms [1]. EPI is characterised by
severely decreased secretion of pancreatic digestive enzymes (i.e.,
amylase, lipase, colipase, proteases, and phospholipases), and
bicarbonate due to impaired fluid secretion and obstruction of
pancreatic ducts by dehydrated aggregates of pro-enzymes [2,3].
Pancreatic dysfunction is thought to be the main cause of severe
malabsorption and poor nutrition in CF. Clinical manifestations of
EPI include poor fat and protein absorption and hence high faecal
excretion of fat and nitrogen, high faecal weight, increased stool
frequency and poor weight gain. Malnourishment and pancreatic
insufficiency have been associated with reduced lung function and
poor clinical course [4,5].
Pancreatic enzymes products (PEPs) have been used for
several decades in the treatment of patients with EPI associated
with CF or other conditions [6]. These preparations contain
mixtures of pancreatic lipase, amylase, protease, and other
pancreas-derived proteins and nucleic acids [7]. Conventionale CC BY-NC-ND
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partially effective in relieving EPI symptoms as pancreatic
enzymes were inactivated by pepsin and gastric acidity [8].
These observations prompted development of enteric-coated tablets
and later, enteric-coated microspheres. These products dissolve at a
pH N5.5, allowing intact passage through the stomach with
dissolution and activation in the higher pH of the duodenum.
This study compared two enteric-coated PEPs, Zenpep 25,000
lipase units (APT-1008, awaiting approval in the European Union,
to be marketed as Enzepi®), and the comparator, Kreon® 25,000
lipase units. Both Zenpep and Kreon are porcine-derived
pancreatic enzyme products containing various enzymes with
proteolytic, lipolytic, and amylolytic activity [9]. PEPs are dosed
based on lipase activity (in terms of lipase units). Lipase is,
however, unstable in the presence of moisture and degrades over
time, meaning that an overage as high as 160% (as overfill) has
historically been included in PEPs, including Kreon. Zenpep,
aligned with the Committee for Medicinal Products for Human
Use guideline on the clinical development of medicinal products
for the treatment of CF [10], is a novel moisture-resistant PEP
formulated to reliably contain between 90% to 110% labelled
lipase content over the shelf life of the product, without overfill.
This distinctive feature enables more accurate dosing, both
providing more predictable therapeutic effects and reducing the
risk of overdose, which is discussed as a potential risk factor for
fibrosing colonopathy, a rare and serious condition [11]. The
primary objective of this study was to evaluate the safety and
efficacy of Zenpep compared with Kreon in the treatment of
CF-associated EPI in patients aged 12 years and older who were
able to swallow the capsules whole.2. Patients and methods
This was a randomised, double-blind, active-controlled,
crossover, multinational, non-inferiority study comparing Zenpep
and Kreon (each capsule containing approximately 25,000 Ph. Eur.
lipase units) in the treatment of CF-associated EPI with CF in
patients aged 12 years and older (NCT01641393). The study was
conducted at 34 sites in seven European countries including
Belgium, Bulgaria, Germany, Hungary, Italy, Poland, and the UK.
The study was conducted in compliance with the clinical study
protocol and in accordance with the International Conference on
Harmonisation (ICH) guidelines for Good Clinical Practice (GCP),
the ICH Tripartite Guideline for GCP, and the Declaration of
Helsinki. Informed consent was obtained from each patient (or
parent/legal guardian for minors) before study entry.
Inclusion criteria included definitive diagnosis of CF based on
one clinical feature consistent with CF and either a genotype with
two identifiable disease-causing CFmutations or a sweat chloride
concentration N60 mmol/L. Other inclusion criteria were pan-
creatic insufficiency documented by a monoclonal faecal elastase
≤100 μg/g stool at screening, current treatment with pancreatic
enzyme replacement therapy, and adequate nutritional status
based on a body mass index (BMI) N19 kg/m2 in adult patients
or a BMI ≥10th percentile for age in adolescents aged
12–17 years. Exclusion criteria included patients with clinicallysignificant cardiac, renal, neurological, gastrointestinal (e.g.,
fibrosing colonopathy), hepatic, or endocrine disease.
The primary efficacy variable was the coefficient of fat
absorption over 72 h (CFA-72 h) calculated from dietary fat
intake and stools collected during the last 3 days (72 consecutive
hours) of each treatment period. The secondary efficacy variables
were: change in body weight, coefficient of nitrogen absorption
over 72 h (CNA-72 h), signs and symptoms of EPI as recorded in
patient diaries, and impact on overall health, daily life, perceived
well-being, and CF symptoms as evaluated by the Cystic Fibrosis
Questionnaire-Revised (CFQ-R).
Patients entered the study with an established PEP regimen. In
consultation with a dietician, a daily 100 g (±15 g) fat diet was
assigned and maintained throughout the study. The 96 eligible
patients (mean age 19.2 years, 60.4% males) were randomised to
one of two treatment sequences of 28 days (±2 days), group A or
B. Patients in group A received Zenpep in treatment period 1 and
crossed over to Kreon in treatment period 2; patients in group B
received the two study drugs in reverse order. In treatment period
1, patients began the assigned treatment (Kreon or Zenpep,
depending on treatment sequence) at a dose as close as possible to
their established PEP treatment (Fig. 1). No washout periods were
included in this study as any residual lipase from the prior
treatment period was considered to have had a negligible influence
on the subsequent CFA-72 h determination. Daily dose could be
rounded up from the initial dose to the nearest number of capsules
to a maximum of 10,000 lipase units/kg of body weight per day or
4000 lipase units/g of fat ingested per day, not to exceed a dose of
10,000 lipase units/kg of body weight per day, in which case the
dose was rounded down to the nearest number of whole capsules.
Dosage adjustment to relieve clinical symptoms was permitted
during the first 2 weeks of each treatment period. In treatment
period 2, patients began the assigned treatment at the same starting
dose used for treatment period 1. Throughout the study, patients
were required to abstain from nutritional supplements containing
high concentrations of (≥30%) medium-chain triglycerides
[12,13].
Stool samples were collected in a hospital/clinic or other
controlled environment to ensure adherence to the prescribed
diet and quantitative stool collection. Stools were collected for
72 consecutive hours starting on the morning of day 26
(±2 days) of each of the 28-day (±2 days) treatment periods.
Stool fat and nitrogen were measured, and the coefficient of fat
absorption (CFA) and coefficient of nitrogen absorption (CNA)
were calculated. Percent CFA was calculated as: percent CFA =
{[dietary fat intake (grams) − stool fat excretion (grams)] /
dietary fat intake (grams)} × 100 [13].
CNA-72 h was calculated, similarly to CFA, at the end of
each treatment period, based on dietary protein intake and
protein excretion data from the stools collected during the last
72 h of each treatment period. Protein content in the stool was
assessed by a specialised central laboratory by means of the
Dumas combustion method [14].
Patients recorded in a diary the frequency and characteristics
of stools and symptoms suggestive of malabsorption including
bloating, abdominal pain, and flatulence. Entries from the last
2 weeks of each treatment period were used in the efficacy
Fig. 1. Study design. CF, cystic fibrosis.
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record information regarding dietary and medication adherence.
During each treatment period, patients were required to record
in a diary each dose of study drug taken. Treatment adherence,
defined as percentage ≥75% and ≤125% of capsules taken
versus capsules prescribed, was determined on the basis of
diary entries and study drug reconciliation and was evaluated at
each visit.
The Cystic Fibrosis Questionnaire-Revised (CFQ-R) was
administered to assess the impact of the treatment on overall
health, daily life, perceived well-being, and symptoms. Parents
and caregivers of children aged 13 years and younger received
the CFQ-R-Parent version of the questionnaire; adults and
adolescents aged 14 years and older received the CFQ-R-Teen/
Adult version. The CFQ-R was completed at the beginning of
each treatment period and at the end of the study.
Statistical analysis was performed using SAS® version 9.3
(SAS Institute Inc., Cary, NC, USA). The choice of 5% as the
non-inferiority margin for CFA-72 h was based on the differ-
ences observed between Kreon and placebo in three randomised
double-blind trials [15–17]. The primary efficacy analysis of
CFA-72 h was based on the completers population, defined as
all randomised patients who received at least one dose of Zenpep
or Kreon and finished both treatment periods with complete
CFA-72 h data.
Mixed linear models were used to analyse CFA-72 h, body
weight changes, CNA-72 h, average number of stools per day,
and CFQ-R scores. Logistic regression models with repeated
proportions were used to analyse stool consistency, visible fat/
grease in stools, and symptoms of abdominal pain, flatulence,
and bloating.
3. Results
Of the 96 patients randomised, 86 completed the study, and
CFA-72 h data were available from both treatment periods for
83 patients (completers population; Fig. 2) Patient mean age at
screening in the 96 patients randomised was 19.2 years (SD 7.9)
and 60.4% were male. Demographics and baseline characteristicswere well balanced between groups A and B (Table 1). In the
completers population, all patients achieved a study drug
compliance level of≥80% during the 72-h stool collection period
and all (100% with Zenpep) or nearly all (98.8% with Kreon)
patients achieved this level of compliance during the treatment
period.
For the primary efficacy variable (CFA-72 h at the end of each
treatment period), Zenpep demonstrated both non-inferiority and
equivalence to Kreon in dietary fat absorption (least-squares [LS]
mean CFA-72 h: Zenpep, 84.1% [SE 1.1] vs. Kreon, 85.3% [SE
1.1]; difference in LS means: −1.3% (95% CI, −3.6 to 1.1) p =
0.297; Table 2). The lower limit of the CI (3.6%) exceeded the
non-inferiority margin of 5%, and the 95% CI was completely
between −5% and 5% and included 0 to show equivalency.
Non-inferiority of Zenpep to Kreon was demonstrated; further-
more, the equivalence of the two drugs also was demonstrated.
Efficacy results of Zenpep and Kreon also were similar for
the secondary endpoints. Overall, the LS mean CNA-72 h
values were similar for Zenpep (80.9% [SE 1.2]) and Kreon
(82.0 [SE 1.2]), with a difference in LS means of −1.1 and a
95% CI (−3.3 to 1.2) and p = 0.334 (Table 2) Patients began the
study with a mean baseline body weight of 54.1 kg. No difference
in change in body weight from baseline was observed with
Zenpep and Kreon (54.6 kg) at end of treatment. Both drugs
resulted in an overall LS mean gain in body weight of 0.5 kg.
Signs and symptoms of EPI on treatment were not significantly
different between Zenpep and Kreon. The average number of
stools per day was similar for Zenpep (1.5 [SE 0.1]) and for Kreon
(1.5 [SE 0.1]), resulting in a difference in LSmeans of 0.02, with a
95% CI (−0.05, 0.09) and p = 0.636. A nominally significant
difference in the proportion of patient-days (i.e., the number of
days that a symptom of any severity was reported divided by the
total number of days that the symptom diary was completed) with
bloating was observed between Zenpep and Kreon (p = 0.007),
with the majority being reported as mild with both treatments;
however, patient-days with bloating were infrequent with both
Zenpep (0.2 overall mean proportion) and Kreon (0.1).
Zenpep and Kreon had a similar impact on overall health,
perceived well-being, and CF symptoms as measured by the
Fig. 2. Patient disposition, consort diagram. aMissing data for coefficient of fat
absorption over 72 h (CFA-72 h) for three patients. bMissing CFA-72 h data
for one patient. cMissing CFA-72 h data for two patients.
Table 2
Analysis of CFA-72 h (%), CNA-72 h (%), and change in body
weight—completers population.
Zenpep Kreon
(N = 83) (N = 83)
CFA-72 h, LS mean (SE) 84.1 (1.1) 85.3 (1.1)
Difference in LS means, 95% CI −1.3 (−3.6, 1.1), p = 0.297
CNA-72 h, LS mean (SE) 80.9 (1.2) 82.0 (1.2)
Difference in LS means, 95% CI −1.1 (−3.3, 1.2), p = 0.334
Change in body weight, LS mean kilograms (SE) 0.5 (0.1) 0.5 (0.1)
Difference in LS means, 95% CI 0.0 (−0.2, 0.2), p = 0.966
CFA-72 h, coefficient of fat absorption over 72 h; CNA-72 h, coefficient of
nitrogen absorption over 72 h; LS, least-squares.
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ences were observed between Zenpep and Kreon for any
domains of the CFQ-R-Parent. For the CFQ-R-Teen/Adult, a
nominally significant difference in favour of Zenpep was
observed only for the respiratory domain, with a higher LS
mean change from baseline for Zenpep (6.8) than for Kreon
(3.7), a 95% CI of the difference in LS mean changes (0.4, 5.9)
and p = 0.026.
Treatment with Zenpep was generally safe and well tolerated.
The safety results seen in this study were consistent with the
known profile of Zenpep and comparable to Kreon. The
proportion of patients reporting treatment-emergent adverse
events (TEAEs) was relatively low with both treatments. The
number of patients reporting TEAEs was numerically lower for
Zenpep than for Kreon, 18 (19.6%) vs. 23 (25.6%), respectively.
In five patients (5.4%) taking Zenpep and eight patients (8.9%)
receiving Kreon, observed TEAEs were consistent with the
underlying disease, with abdominal pain, diarrhoea, and flatu-
lence reported most frequently. Most TEAEs were reported at a
maximum intensity of mild. Investigators reported no serious
adverse events (AEs) related to treatment and no deaths.Table 1
Patient demographics and baseline characteristics—intention-to-treat population.
Characteristic Group A
Zenpep/Kreon
(N = 48)
Age, mean (range) year 20.4 (12–42)
Male, n (%) 29 (60.4)
CF diagnosis based on, n (%)
Clinical feature plus 48 (100.0)
Genotype with 2 CF mutations OR 40 (83.3)
Sweat chloride N60 mmol/L 36 (75.0)
Monoclonal faecal elastase b15 μg/g, n (%) 36 (75.0)
Body weight, mean (SD) kg 53.3 (13.3)
CF, cystic fibrosis; EPI, exocrine pancreatic insufficiency.4. Discussion
Overall, Zenpep demonstrated efficacy comparable with
Kreon. Specifically, Zenpep demonstrated both non-inferiority
and equivalence to Kreon in terms of control of dietary fat
absorption (assessed as CFA-72 h). Kreon and Zenpep, which
produced with no overfill, showed marginal differences
in lipase activity. Kreon 10,000 lipase units was originally
selected as the comparator to Zenpep 10,000 lipase units for
this study; however, certificates of analysis revealed that Kreon
contained a 40% to 50% overfill of lipase. Therefore, after the
first patient was randomised, the study was stopped. To address
this issue of overfill, a new comparator drug formulation,
Kreon 25,000 lipase units, was tested and had less than 10%
overfill; thus the study was re-started and used Kreon 25,000
lipase units and Zenpep 25,000 lipase units.
The efficacy results of Zenpep demonstrated in this study are
broadly similar to those reported previously. In a placebo-
controlled study involving 32 patients (mean age 15.4 years)
with CF-associated EPI, 29 (91%) achieved an LS mean CFA
above 80% after a 6- to 7-day treatment with Zenpep (LS mean
CFA-72 was 88.3%) [18]. For the 83 completers in our study,
the LS mean CFA-72 h was 84.1%. In the placebo-controlled
study, an LS mean CNA of 87.2% was reported, a result that is
broadly comparable to the LS mean CNA-72 h of 80.9% found
for the completers population in our study.Group B Total
Kreon/Zenpep (N = 96)
(N = 48)
18.0 (12–43) 19.2 (12–43)
29 (60.4) 58 (60.4)
48 (100.0) 96 (100.0)
44 (91.7) 84 (87.5)
39 (81.3) 75 (78.1)
38 (79.2) 74 (77.1)
53.8 (13.9) 53.6 (13.5)
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published data. In a placebo-controlled study, 97 patients (aged
7 years and older) with CF-associated pancreatic insufficiency
and steatorrhoea, received a high-fat diet and Kreon. After the
patients had been stabilised, those with a CFA greater than 80%
either continued with Kreon or received a placebo during a 72-h
stool collection phase. In the Kreon group, patients maintained a
mean CFA of 84.1%, whereas placebo was associated with a drop
in mean CFA to 52.2% [19]. In a double-blind, placebo-controlled
crossover study involving 32 patients with CF-associated EPI,
5 days of Kreon resulted in an LS mean CFA of 88.6% and an LS
mean CNA of 85.1% [17]. In our study, results for the completers
population were broadly similar, with LS means for CFA-72 h of
85.3% and CNA-72 h of 82.0% with Kreon.
Signs and symptoms associated with EPI, evaluated as
secondary endpoints, showed that the proportion of patient-days
with abdominal pain or flatulence with Zenpep was comparable to
those seen with Kreon (Table 3). Abdominal pain and flatulence
was of mild intensity in the majority of subjects with both
treatments; however, a nominally significant difference in the
proportion of patient-days with bloating was observed between
Zenpep and Kreon (p = 0.007). The overall mean proportion of
patient-days with bloating was low with both treatments (0.2 with
Zenpep and 0.1 with Kreon), and the majority of bloating was
of mild intensity with both treatments; therefore, the clinical
significance of the difference in bloating is unclear. Zenpep and
Kreon had similar effects on stool frequency, stool consistency,
and visible fat/grease in the stool. For the CFQ-R-Teen/Adult, a
nominally significant difference in favour of Zenpepwas observed
only for the respiratory domain, with a higher LS mean change
from baseline for Zenpep than for Kreon (p = 0.026). Otherwise,
Zenpep and Kreon showed a similar impact on overall health,
perceived well-being, and CF symptoms as measured by the
CFQ-R-Parent and CFQ-R-Teen/Adult.
The safety and tolerability of Zenpep was comparable to
Kreon, with a numerically lower number of patients experiencing
TEAEs with Zenpep. The safety findings for Zenpep in this study
were consistent with the established safety profile summarised
in the Zenpep US prescribing information. The most common
known AEs (N6% of patients treated with Zenpep) are abdominal
pain, flatulence, headache, cough, decreased weight, early satiety,Table 3
Analysis of patient-reported signs and symptoms over the last 2 weeks of the
treatment period—completers population.
Zenpep Kreon p-value
(N = 83) (N = 83)
Stool frequency per day, LS mean (SE) 1.5 (0.1) 1.5 (0.1) 0.636
Proportion of days with:
Hard + formed/normal stool consistency,
mean (SD)
0.7 (0.3) 0.8 (0.3) 0.698
Stools with visible fat/grease, mean (SD) 0.1 (0.1) 0.1 (0.2) 0.826
Bloating, mean (SD) 0.2 (0.3) 0.1 (0.2) 0.007
Abdominal pain, mean (SD) 0.1 (0.2) 0.1 (0.2) 0.691
Flatulence, mean (SD) 0.4 (0.4) 0.4 (0.4) 0.445
LS, least-squares.and contusion [19,20]. Gastrointestinal events, including abdom-
inal pain and flatulence, were the most frequently reported TEAEs
in this study; however, no instances of weight loss, early satiety, or
contusion were reported. None of the TEAEs in this study occurred
at a rate of more than 3.3%, underscoring the favourable safety
profile of Zenpep.
5. Conclusions
Zenpep demonstrated both non-inferiority and equivalence
to Kreon in the primary endpoint of dietary fat absorption.
Further, efficacy results of Zenpep and Kreon were generally
similar for the secondary endpoints. TEAEs were consistent
with the known profile of Zenpep and comparable to Kreon.
The distinctive lack of enzyme overfill with Zenpep enables
more accurate dosing, thereby providing more predictable
therapeutic effects. Moreover, with the increasing use of
high-dose PEPs containing a stated dose of 25,000–40,000
lipase units/capsule, dosages in excess of the recommended
10,000 U lipase/Kg are easily reached. As this has been
described as a potential risk factor for fibrosing colonopathy,
more exact PEP dosing with zero overfill could theoretically
reduce this risk.
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